Immune Design to Report Third Quarter 2018 Financial Results and Provide Corporate Update
October 30, 2018 08:00 ET
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced that it...
Immune Design Announces Program Updates & Portfolio Prioritization for G100 and CMB305
October 11, 2018 16:01 ET
|
Immune Design Corp.
G100 development to accelerate in follicular lymphoma and beyondCMB305 to be deprioritized to support focus on G100Cash runway extended into 2021Conference call at 2:00 pm Pacific today SEATTLE and...
Immune Design to Present at Upcoming September Investor Conferences
August 30, 2018 08:00 ET
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on novel therapies in oncology, today announced that senior...
Immune Design Reports Second Quarter 2018 Financial Results and Provides Corporate Update
August 01, 2018 16:01 ET
|
Immune Design Corp.
G100 advancing to late-stage development following FDA feedbackConference call at 1:30 pm Pacific today SEATTLE, WA and SOUTH SAN FRANCISCO, CA, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Immune Design...
Immune Design to Report Second Quarter 2018 Financial Results and Provide Corporate Update
July 25, 2018 08:00 ET
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Calif., July 25, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced...
Immune Design Presents Data on the Mechanism of Action of G100 via TLR4 Expressed in B Cell Malignancies at the Inaugural AACR International Meeting Advances in Malignant Lymphoma
June 25, 2018 08:00 ET
|
Immune Design Corp.
- G100 directly targets and modifies TLR4 expressing malignant B cells making them more visible to the anti-tumor immune response- SEATTLE and SOUTH SAN FRANCISCO, Calif., June 25, 2018 (GLOBE...
Immune Design to Host June 4 Cancer Immunotherapy Event in Chicago and Present at Jefferies 2018 Global Healthcare Conference in New York
June 01, 2018 08:00 ET
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Calif., June 01, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), an immunotherapy company focused on novel therapies in oncology, today announced that the...
Immune Design Announces Launch of Web Portal for SYNOVATE Phase 3 Study of CMB305 Immunotherapy in Synovial Sarcoma
May 24, 2018 08:00 ET
|
Immune Design Corp.
-- 1st global Phase 3 trial focused on synovial sarcoma patients -- www.synovatestudy.com SEATTLE and SOUTH SAN FRANCISCO, Calif., May 24, 2018 (GLOBE NEWSWIRE) -- Immune...
Immune Design Reports First Quarter 2018 Financial Results and Provides Corporate Update
May 02, 2018 16:01 ET
|
Immune Design Corp.
The higher dose of CMB305 was deemed safe and cleared for the pivotal Phase 3The 20ug dose of G100 shows a two-fold increase in TILs, higher than that seen at the 10ug doseConference call at 1:30 pm...
Immune Design to Report First Quarter 2018 Financial Results and Provide Corporate Update
April 25, 2018 08:00 ET
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Calif., April 25, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced...